Veterinary prescription fees will be capped across the UK as the Competition and Markets Authority (CMA) moves to tackle market concentration that has driven up costs for Britain's 16 million pet-owning households. The intervention, following a comprehensive market investigation launched this year, targets a sector where prescription charges can exceed £30 per item—a significant burden for owners of pets requiring regular medication.
The CMA's investigation has revealed substantial market consolidation, with large corporate groups acquiring independent practices at an accelerated pace. This consolidation has created potential conflicts of interest around medicine prescribing and dispensing, whilst limiting competitive pricing across services. The prescription fee cap aims to enable pet owners to source medications from alternative providers, including online pharmacies, delivering immediate cost savings on essential treatments.
The regulatory package extends beyond fee caps to address structural market issues. New transparency requirements will mandate disclosure of practice ownership, ensuring clients understand whether their veterinary surgery operates as part of a larger corporate entity. Enhanced information provision measures are also under consideration, designed to equip pet owners with comparable pricing data and enable more informed healthcare decisions for their animals.
The investigation was triggered by an initial review that generated over 56,000 public responses—an unprecedented level of engagement highlighting acute consumer concern. Respondents consistently reported sharp increases in veterinary bills alongside insufficient pricing transparency, with many unable to effectively compare services or costs. The CMA's preliminary analysis indicates current market structures may be constraining competition, directly impacting both pricing levels and service quality.
For UK households, these reforms could deliver substantial financial relief, particularly for owners managing chronic pet conditions requiring ongoing medication. The ability to source prescriptions independently of veterinary practices represents a significant cost reduction opportunity. Combined with enhanced ownership transparency and clearer pricing frameworks, these measures should restore competitive dynamics whilst empowering consumers to navigate veterinary care costs more effectively.